{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T05:09:14Z","timestamp":1777093754630,"version":"3.51.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100019084","name":"Kobe University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019084","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objectives<\/jats:title>\n            <jats:p>Prostate cancer patients receiving androgen deprivation therapy (ADT) have increased risks of decreased bone mineral density (BMD). However, there are no established guidelines for assessing BMD in patients with bone metastases. The aim of this study was to assess the effects of ADT on bone health by comparing longitudinal changes in BMD between prostate cancer patients with and without bone metastases.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A single-center observational study was conducted from February 2020 to January 2023 at Kobe University Hospital. BMD at the lumbar vertebrae, total hip, and femoral neck was measured at baseline, 6, and 12 months using dual-energy X-ray absorptiometry. Bones were classified into Metastatic Site (with metastases), Non-metastatic Sites (from patients with bone metastases), and Control (patients without metastases) groups. All patients received luteinizing hormone-releasing hormone antagonists or agonists plus oral ARSI or bicalutamide for 1 year.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Among the 78 patients, 35, 110, and 245 bones were classified into the Metastatic Site group, Non-metastatic Sites group, and Control group, respectively. The Metastatic Site group exhibited significantly higher T-scores compared with the other groups (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). Repeated measures analysis revealed a statistically significant reduction in T-scores over time across all groups (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). However, no significant interaction was observed between group classification and time (<jats:italic>P<\/jats:italic>\u2009=\u20090.817).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The present study demonstrates that BMD changes at non-metastatic sites in patients with bone metastases are similar to those in patients without metastases. Monitoring BMD at non-metastatic sites may provide valuable insights into ADT's effects on bone health in prostate cancer patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s10147-025-02711-7","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T09:19:02Z","timestamp":1738919942000},"page":"797-804","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Longitudinal assessment of bone mineral density in prostate cancer patients: comparing metastatic and non-metastatic regions"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4524-2815","authenticated-orcid":false,"given":"Takuto","family":"Hara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanako","family":"Nishimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoaki","family":"Terakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyoshi","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukari","family":"Bando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideto","family":"Ueki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kotaro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoji","family":"Hyodo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Teishima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryosuke","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"key":"2711_CR1","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3892\/ol.2023.13749","volume":"25","author":"EA Goode","year":"2023","unstructured":"Goode EA, Wang N, Munkley J (2023) Prostate cancer bone metastases biology and clinical management (review). Oncol Lett 25:163","journal-title":"Oncol Lett"},{"key":"2711_CR2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1677\/erc.1.00775a","volume":"12","author":"Z Culig","year":"2005","unstructured":"Culig Z, Steiner H, Bartsch G et al (2005) Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours. Endocr Relat Cancer 12:229\u2013244","journal-title":"Endocr Relat Cancer"},{"key":"2711_CR3","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.3390\/cancers15051518","volume":"15","author":"C Baldessari","year":"2023","unstructured":"Baldessari C, Pipitone S, Sabbatini R et al (2023) Bone metastases and health in prostate cancer: from pathophysiology to clinical implications. Cancers (Basel) 15:1518","journal-title":"Cancers (Basel)"},{"key":"2711_CR4","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","volume":"67","author":"PL Nguyen","year":"2015","unstructured":"Nguyen PL, Alibhai SMH, Smith MR et al (2015) Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol 67:825\u2013836","journal-title":"Eur Urol"},{"key":"2711_CR5","doi-asserted-by":"crossref","first-page":"6410","DOI":"10.1210\/jc.2005-0183","volume":"90","author":"SL Greenspan","year":"2005","unstructured":"Greenspan SL, Coates P, Sereika SM et al (2005) Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 90:6410\u20136417","journal-title":"J Clin Endocrinol Metab"},{"key":"2711_CR6","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1186\/s12885-015-1843-3","volume":"15","author":"A Wang","year":"2015","unstructured":"Wang A, Obertov\u00e1 Z, Brown C et al (2015) Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand. BMC Cancer 15:837","journal-title":"BMC Cancer"},{"key":"2711_CR7","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.annepidem.2008.07.003","volume":"18","author":"ME Mussolino","year":"2008","unstructured":"Mussolino ME, Gillum RF (2008) Low bone mineral density and mortality in men and women: the Third National Health and Nutrition Examination Survey linked mortality file. Ann Epidemiol 18:847\u2013850","journal-title":"Ann Epidemiol"},{"key":"2711_CR8","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00774-020-01087-0","volume":"38","author":"S Fukumoto","year":"2020","unstructured":"Fukumoto S, Soen S, Matsumoto T et al (2020) Subcommittee for CTIBL in the JSBMR. Management manual for cancer treatment-induced bone loss (CTIBL): position statement of the JSBMR. J Bone Miner Metab 38:141\u2013144","journal-title":"J Bone Miner Metab"},{"issue":"Suppl 3","key":"2711_CR9","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/annonc\/mdu103","volume":"25","author":"R Coleman","year":"2014","unstructured":"Coleman R, Body JJ, Aapro M et al (2014) Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 25(Suppl 3):124\u2013137","journal-title":"Ann Oncol"},{"key":"2711_CR10","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0022-5347(05)64985-3","volume":"167","author":"A Berruti","year":"2002","unstructured":"Berruti A, Dogliotti L, Tarabuzzi R et al (2002) Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 167:2361\u20132367","journal-title":"J Urol"},{"key":"2711_CR11","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0022-5347(01)61639-2","volume":"161","author":"JF Maillefert","year":"1999","unstructured":"Maillefert JF, Sibilia J, Michel F et al (1999) Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 161:1219\u20131222","journal-title":"J Urol"},{"key":"2711_CR12","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1007\/s00774-024-01537-z","volume":"42","author":"T Hara","year":"2024","unstructured":"Hara T, Nishimoto H, Miyake H et al (2024) Temporal declines in bone mineral density and trabecular bone score during androgen deprivation therapy. J Bone Miner Metab 42:668","journal-title":"J Bone Miner Metab"},{"key":"2711_CR13","doi-asserted-by":"crossref","first-page":"5417","DOI":"10.3390\/cancers13215417","volume":"13","author":"A Jacob","year":"2021","unstructured":"Jacob A, Raj R, Allison DB et al (2021) Androgen receptor signaling in prostate cancer and therapeutic strategies. Cancers (Basel) 13:5417","journal-title":"Cancers (Basel)"},{"key":"2711_CR14","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00774-013-0447-8","volume":"31","author":"S Soen","year":"2013","unstructured":"Soen S, Fukunaga M, Sugimoto T et al (2013) Diagnostic criteria for primary osteoporosis: year 2012 revision. J Bone Miner Metab 31:247\u2013257","journal-title":"J Bone Miner Metab"},{"key":"2711_CR15","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely-available easy-to-use software \u201cEZR\u201d (Easy R) for medical statistics. Bone Marrow Transplant 48:452\u2013458","journal-title":"Bone Marrow Transplant"},{"key":"2711_CR16","first-page":"112","volume":"3","author":"C Bagi","year":"2003","unstructured":"Bagi C (2003) Skeletal implications of prostate cancer. J Musculoskelet Neuronal Interact 3:112\u2013117","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"2711_CR17","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41391-020-00296-y","volume":"24","author":"A Hussain","year":"2021","unstructured":"Hussain A, Tripathi A, Guise T et al (2021) Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 24:290\u2013300","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2711_CR18","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.euo.2024.01.016","volume":"7","author":"C Jones","year":"2024","unstructured":"Jones C, Gray S, Sachdeva A et al (2024) Risk of fractures and falls in men with advanced or metastatic prostate cancer receiving androgen deprivation therapy and treated with novel androgen receptor signaling inhibitors: a systematic review and meta-analysis of randomized controlled trials. Eur Urol Oncol. 7:993","journal-title":"Eur Urol Oncol."},{"key":"2711_CR19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104817","volume":"97","author":"K David","year":"2023","unstructured":"David K, Devos G, Deboel L et al (2023) Changes in bone and mineral homeostasis after short-term androgen deprivation therapy with or without androgen receptor signalling inhibitor\u2014substudy of a single-centre, double blind, randomised, placebo-controlled phase 2 trial. EBioMedicine 97:104817","journal-title":"EBioMedicine"},{"issue":"6_Suppl","key":"2711_CR20","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1200\/JCO.2022.40.6_suppl.019","volume":"40","author":"R Guilhem","year":"2022","unstructured":"Guilhem R, Marie K, Karim F et al (2022) Bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone plus prednisone in the PEACE-1 phase 3 trial. J Clin Oncol 40(6_Suppl):19\u201319","journal-title":"J Clin Oncol"},{"key":"2711_CR21","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.urolonc.2007.05.027","volume":"26","author":"H Perk","year":"2008","unstructured":"Perk H, Yildiz M, Ozorak A et al (2008) Correlation between BMD and bone scintigraphy in patients with prostate cancer. Urol Oncol 26:250\u2013253","journal-title":"Urol Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02711-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02711-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02711-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T14:58:29Z","timestamp":1743260309000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02711-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["2711"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02711-7","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,7]]},"assertion":[{"value":"7 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hideaki Miyake has received payments for lectures from Merck, Janssen, and Takeda. Takuto Hara, Hanako Nishimoto, Tomoaki Terakawa, Yasuyoshi Okamura, Kotaro Suzuki, Yukari Bando, Koji Chiba, Yoji Hyodo, Jun Teishima, and Ryosuke Kuroda declare that no competing interests exist.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Committee of Kobe University (IRB No. B190287).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients provided verbal informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Registration of trial"}}]}}